Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 16,851 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Multiple Sclerosis
Interventions: ACTHAR; Drug
Lead sponsor: Elliot Frohman; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Coronary Arteriosclerosis, Acute Coronary Syndromes
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 13,619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV Infection, Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Dry Eye Disease
Interventions: Omega-3 (Triglyceride form); Dietary Supplement
Lead sponsor: Physician Recommended Nutriceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neonatal Opiate Withdrawal Syndrome
Interventions: Finnegan Neonatal Abstinence Scoring Tool, Eat, Sleep, Console (ESC) care tool; Other
Lead sponsor: Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program; Network
Eligibility: Up to 3 Days
Enrollment: 1,305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Newark, Delaware • Tampa, Florida • Honolulu, Hawaii + 21 more

Conditions: HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: HIV Infection
Interventions: Nevirapine; Drug
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression, Depressive Disorder, Metabolic Syndrome
Interventions: Exercise; Behavioral
Lead sponsor: California State University, San Marcos; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Marcos, California

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: TDF/FTC; Drug
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections, Sexually Transmitted Infections
Interventions: Male Sexual Health Program, Focus on the Future Program; Behavioral
Lead sponsor: Richard Crosby; Other
Eligibility: 15 Years to 23 Years · Male only
Enrollment: 840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions: anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: Behavioral intervention to reduce sexual risk among African-American men who have sex with men; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Morquio Disease, Mucopolysaccharidosis IV
Interventions: Not listed
Lead sponsor: Nadia Ali, PhD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
Interventions: CWP232291; Drug
Lead sponsor: JW Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Obesity, Metabolic Syndrome
Interventions: Weight loss; Other
Lead sponsor: Auburn University; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Poliomyelitis, Postpoliomyelitis Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1982 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV, Depression, HIV Infections
Interventions: COMB - Combination Cognitive Behavioral Therapy and Medication Management, TAU - Treatment as Usual; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Tampa, Florida • The Bronx, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma, Wilms' Tumor, Neuroblastoma
Interventions: ODSH; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 1 Year to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Tourette Syndrome
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Neurofibromatosis Type 1, Neurofibromatosis 1, Plexiform Neurofibroma, Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumors, Atypical Neurofibroma
Interventions: Liquid biopsy for MPNST development; Diagnostic Test
Lead sponsor: David Miller; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 1,980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 24
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more

Conditions: Exocrine Pancreatic Insuficiency
Interventions: Fecal Fat; Diagnostic Test
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Contraception, Hiv
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease

Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight

Does Antidepressant Use Blunt Adaptations to Exercise?

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

HIV Prevention Program for African American Teen Males

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men

Psychological Concomitants of Morquio Syndrome (The MAP Study)

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome

Study of "Post-Polio Syndrome"

Treatment for Depression Among HIV-Infected Youth

ODSH + ICE Chemotherapy in Pediatric Solid Tumors

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Neurofibromatosis Type 1 Tumor Early Detection Study

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

Contraceptive/HIV Affecting Risk in Adolescents